Kristin Abate

CIK: 0002045943

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)12 (70.6%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (29.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KPTI

Karyopharm Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

KPTI
Karyopharm Therapeutics Inc.
Oct 16, 2026
Sale(S)
Direct
4.8K shares at avg. $0.34$2K
KPTI
Karyopharm Therapeutics Inc.
Oct 1, 2026
Sale(S)
Direct
378 shares at avg. $1.19$449.82
KPTI
Karyopharm Therapeutics Inc.
Sep 1, 2026
Sale(S)
Direct
19 shares at avg. $2.02$38.38
KPTI
Karyopharm Therapeutics Inc.
May 14, 2026
Sale(S)
Direct
53 shares at avg. $9.50$503.5
KPTI
Karyopharm Therapeutics Inc.
May 13, 2026
Award(A)
Direct
121 shares-
KPTI
Karyopharm Therapeutics Inc.
Mar 2, 2026
Sale(S)
Direct
559 shares at avg. $9.41$5K
KPTI
Karyopharm Therapeutics Inc.
Jan 28, 2026
Sale(S)
Direct
50 shares at avg. $7.03$351.5
KPTI
Karyopharm Therapeutics Inc.
Jan 27, 2026
Award(A)
Direct
92 shares-
KPTI
Karyopharm Therapeutics Inc.
Jan 21, 2026
Sale(S)
Direct
265 shares at avg. $5.96$2K
KPTI
Karyopharm Therapeutics Inc.
Oct 15, 2025
Award(A)
Direct
12.8K shares-
KPTI
Karyopharm Therapeutics Inc.
Oct 1, 2025
Sale(S)
Direct
362 shares at avg. $6.30$2K
KPTI
Karyopharm Therapeutics Inc.
Sep 15, 2025
Sale(S)
Direct
23 shares at avg. $6.43$147.89
KPTI
Karyopharm Therapeutics Inc.
Sep 12, 2025
Award(A)
Direct
46 shares-
KPTI
Karyopharm Therapeutics Inc.
Sep 3, 2025
Sale(S)
Direct
12 shares at avg. $6.78$81.36
KPTI
Karyopharm Therapeutics Inc.
Jul 22, 2025
Sale(S)
Direct
238 shares at avg. $4.00$952
KPTI
Karyopharm Therapeutics Inc.
Mar 4, 2025
Sale(S)
Direct
571 shares at avg. $6.29$4K
KPTI
Karyopharm Therapeutics Inc.
Feb 28, 2025
Award(A)
Direct
933 shares-

		Type	Shares	Price		Ownership
Oct 16, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	4,788	$0.34	$1,647	Direct
Oct 1, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	378	$1.19	$450	Direct
Sep 1, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	19	$2.02	$38	Direct
May 14, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	53	$9.50	$504	Direct
May 13, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	121	-	$0	Direct
Mar 2, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	559	$9.41	$5,260	Direct
Jan 28, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	50	$7.03	$352	Direct
Jan 27, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	92	-	$0	Direct
Jan 21, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	265	$5.96	$1,579	Direct
Oct 15, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	12,799	-	-	Direct
Oct 1, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	362	$6.30	$2,279	Direct
Sep 15, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	23	$6.43	$148	Direct
Sep 12, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	46	-	-	Direct
Sep 3, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	12	$6.78	$81	Direct
Jul 22, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	238	$4.00	$952	Direct
Mar 4, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	571	$6.29	$3,592	Direct
Feb 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	933	-	-	Direct

1-17 of 17 transactions

About Abate Kristin

Abate Kristin (SEC CIK 0002045943) files insider reports with the SEC as Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI).

Signal8 holds 15 ownership filings by Abate Kristin (1 Form 3, 14 Form 4), filed between Nov 22, 2024 and Oct 19, 2026. Those filings report 17 transactions, from Feb 28, 2025 to Oct 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Abate Kristin's filings is in NEWTON, MA.

Recent filings by Abate Kristin

Oct 16, 2026: Open-market sale of KPTI shares (Form 4, code S).
Oct 1, 2026: Open-market sale of KPTI shares (Form 4, code S).
Sep 1, 2026: Open-market sale of KPTI shares (Form 4, code S).
May 14, 2026: Open-market sale of KPTI shares (Form 4, code S).
May 13, 2026: Grant or award of KPTI shares (Form 4, code A).

Other insiders filing for Karyopharm Therapeutics Inc. (KPTI)

Poulton Stuart, EVP, Chief Development Officer
Oliger Christy J., Director
PAKIANATHAN DEEPIKA, Director
Schor Chen, Director
Su Zhen, Director
BOHLIN GAREN G, Director

How to read Form 4 transaction codes